Skip to main content
NCBI home page
Archives of Disease in Childhood logoLink to Archives of Disease in Childhood
editorial
. 1986 Jun;61(6):531–532. doi: 10.1136/adc.61.6.531

Vaccine advances.

J W Smith
PMCID: PMC1777834  PMID: 3729518

Full text

PDF
531

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Hilleman M. R., Provost P. J., Buynak E. B., McLean A. A. Progress toward a live attenuated human hepatitis A virus vaccine. Dev Biol Stand. 1983;54:433–440. [PubMed] [Google Scholar]
  2. Hooke A. M., Bellanti J. A., Oeschger M. P. Live attenuated bacterial vaccines: new approaches for safety and efficacy. Lancet. 1985 Jun 29;1(8444):1472–1474. doi: 10.1016/s0140-6736(85)92252-4. [DOI] [PubMed] [Google Scholar]
  3. Lepow M. L., Samuelson J. S., Gordon L. K. Safety and immunogenicity of Haemophilus influenzae type b-polysaccharide diphtheria toxoid conjugate vaccine in infants 9 to 15 months of age. J Pediatr. 1985 Feb;106(2):185–189. doi: 10.1016/s0022-3476(85)80284-5. [DOI] [PubMed] [Google Scholar]
  4. McAleer W. J., Buynak E. B., Maigetter R. Z., Wampler D. E., Miller W. J., Hilleman M. R. Human hepatitis B vaccine from recombinant yeast. Nature. 1984 Jan 12;307(5947):178–180. doi: 10.1038/307178a0. [DOI] [PubMed] [Google Scholar]
  5. Minor P. D., Schild G. C., Bootman J., Evans D. M., Ferguson M., Reeve P., Spitz M., Stanway G., Cann A. J., Hauptmann R. Location and primary structure of a major antigenic site for poliovirus neutralization. Nature. 1983 Feb 24;301(5902):674–679. doi: 10.1038/301674a0. [DOI] [PubMed] [Google Scholar]
  6. Morgan A. J., Epstein M. A., North J. R. Comparative immunogenicity studies on Epstein-Barr virus membrane antigen (MA) gp340 with novel adjuvants in mice, rabbits, and cotton-top tamarins. J Med Virol. 1984;13(3):281–292. doi: 10.1002/jmv.1890130310. [DOI] [PubMed] [Google Scholar]
  7. Peltola H., Käyhty H., Virtanen M., Mäkelä P. H. Prevention of Hemophilus influenzae type b bacteremic infections with the capsular polysaccharide vaccine. N Engl J Med. 1984 Jun 14;310(24):1561–1566. doi: 10.1056/NEJM198406143102404. [DOI] [PubMed] [Google Scholar]
  8. Sato Y., Kimura M., Fukumi H. Development of a pertussis component vaccine in Japan. Lancet. 1984 Jan 21;1(8369):122–126. doi: 10.1016/s0140-6736(84)90061-8. [DOI] [PubMed] [Google Scholar]
  9. Smith G. L., Mackett M., Moss B. Infectious vaccinia virus recombinants that express hepatitis B virus surface antigen. Nature. 1983 Apr 7;302(5908):490–495. doi: 10.1038/302490a0. [DOI] [PubMed] [Google Scholar]
  10. Vesikari T., Isolauri E., Delem A., D'Hondt E., André F. E., Zissis G. Immunogenicity and safety of live oral attenuated bovine rotavirus vaccine strain RIT 4237 in adults and young children. Lancet. 1983 Oct 8;2(8354):807–811. doi: 10.1016/s0140-6736(83)90734-1. [DOI] [PubMed] [Google Scholar]
  11. Wahdan M. H., Sérié C., Cerisier Y., Sallam S., Germanier R. A controlled field trial of live Salmonella typhi strain Ty 21a oral vaccine against typhoid: three-year results. J Infect Dis. 1982 Mar;145(3):292–295. doi: 10.1093/infdis/145.3.292. [DOI] [PubMed] [Google Scholar]
  12. Weibel R. E., Neff B. J., Kuter B. J., Guess H. A., Rothenberger C. A., Fitzgerald A. J., Connor K. A., McLean A. A., Hilleman M. R., Buynak E. B. Live attenuated varicella virus vaccine. Efficacy trial in healthy children. N Engl J Med. 1984 May 31;310(22):1409–1415. doi: 10.1056/NEJM198405313102201. [DOI] [PubMed] [Google Scholar]

Articles from Archives of Disease in Childhood are provided here courtesy of BMJ Publishing Group

RESOURCES